EBC-46 Mechanism of Action: PKC-Delta, DAG Mimicry, and Vascular Disruption
How tigilanol tiglate activates PKC-delta through diacylglycerol mimicry, triggers vascular disruption, and produces localised tumour necrosis — a mechanistic overview.
Tigilanol tiglate (EBC-46) produces its biological effects through a well-characterised mechanism involving protein kinase C (PKC) activation. Understanding this pathway helps explain the compound's potency in preclinical and pharmaceutical contexts, and why researchers continue to investigate its properties.
PKC-Delta and DAG Mimicry
Tigilanol tiglate belongs to the tigliane diterpene class and acts as a diacylglycerol (DAG) mimetic. DAG is a naturally occurring second messenger that activates members of the protein kinase C (PKC) family — enzymes that phosphorylate target proteins and regulate numerous cellular processes including proliferation, differentiation, and apoptosis.
By mimicking DAG, tigilanol tiglate binds to the C1 domain of PKC isoforms, with particular affinity for PKC-delta and PKC-epsilon. Activation of PKC-delta in particular triggers downstream signalling cascades that promote vascular disruption and localised cell death.
Vascular Disruption
A distinctive feature of tigilanol tiglate's mechanism is rapid vascular disruption at the site of administration. In pharmaceutical studies with Stelfonta (intratumoral injection), the compound caused haemorrhagic necrosis and loss of vascular integrity within hours of administration. This vascular disrupting activity is thought to contribute substantially to the compound's observed effects on localised tissue.
Tumour Necrosis and Immune Activation
Following vascular disruption, the resulting ischaemia and direct cytotoxic effects lead to localised tumour necrosis. Preclinical data also suggest that tigilanol tiglate may activate innate immune responses at the site of action, though the relative contribution of immune mechanisms compared with direct cytotoxicity remains an active area of investigation.
Oral vs. Injectable Considerations
Published mechanistic research used pharmaceutical-grade tigilanol tiglate administered via intratumoral injection — the delivery route used in Stelfonta. Oral absorption, bioavailability, and systemic distribution of blushwood berry extract constituents in supplement form have not been characterised in peer-reviewed clinical studies. This distinction is important context for interpreting mechanistic data in relation to dietary supplement products.
References
1. QBiotics Group — Tigilanol Tiglate Mechanism, mechanism summary.
2. FDA — Stelfonta Approval, pharmacology section.
3. PubMed — PKC-delta signalling research, multiple studies on PKC isoform biology.
Related Articles
For context on the pharmaceutical development pathway, see our complete guide to EBC-46 and tigilanol tiglate. See also Fontainea picrosperma: botanical source of EBC-46.
